The genetically polymorphic CYP2C9 metabolizes many non-steroidal anti-inflammatory agents, including naproxen. This study examined the effects of a CYP2C9 genetic polymorphism on the pharmacokinetics of naproxen in Korean subjects. Twenty healthy male subjects carrying a $CYP2C9^*1/^*1$ (n=14) or $CYP2C9^*1/^*3$ (n=6) polymorphism were enrolled. After a single-dose of 275 mg naproxen Na, blood samples were collected at various times over a 72 h period and the plasma naproxen concentration was measured. The plasma concentration of naproxen was determined by HPLC analysis with UV detection, and the pharmacokinetic parameters were calculated. The mean plasma concentration-time profiles of naproxen in the $CYP2C9^*1/^*3$ and $CYP2C9^*1/^*1$ individuals were similar. There were no significant differences in the pharmacokinetics of naproxen between $CYP2C9^*1/^*1$ and $CYP2C9^*1/^*3$ genotypes. The $AUC_{0-infty}$ (p = 0.759) and oral clearance (p = 0.823) of naproxen were also similar in individuals with $CYP2C9^*1/^*3$ and $CYP2C9^*1/^*1$. Overall, a genetic polymorphism of CYP2C9 does not significantly affect the pharmacokinetics of naproxen. Therefore, naproxen does not require a dose adjustment for individuals with the $CYP2C9^*1/^*3$ genotype.